Pipeline

Committed to the Discovery, Development, and Commercialization of Potentially Transformational Therapies

Amylin continues to expand opportunities for its commercialized products, and focus on innovative new therapies for diabetes and metabolic disease. These are investigational products and are not approved by the U.S. Food and Drug Administration (FDA).

Diabetes

• Amylin is developing exenatide suspension formulations that do not need reconstitution.  A once-weekly and a once-monthly exenatide suspension are in clinical development for the treatment of type 2 diabetes.
• Metreleptin, an analogue of the human hormone leptin, is a potential therapy for the treatment of diabetes and/or hypertriglyceridemia in patients with rare inherited or acquired forms of lipodystrophy. Data from clinical studies demonstrated that metreleptin had profound effects on improving insulin sensitivity, high triglycerides, hyperglycemia and liver fat in patients with lipodystrophy, even when treated with high doses of insulin.
  
  Amylin has submitted the initial sections of a rolling submission for its Biologics License Application (BLA) to the FDA.
• AC165198 is a peptide hybrid (fusion of two different peptide hormones, within a single molecular entity with dual pharmacology) that is moving to clinical development for the potential treatment of diabetes.

Obesity

Amylin has a worldwide agreement with Takeda Pharmaceutical Company Limited to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.

Additional R&D efforts, in collaboration with specialty research firms, are focused on long-term opportunities in diabetes, obesity and other metabolic diseases.